These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Zhu G; Luo H; Feng Y; Guryanova OA; Xu J; Chen S; Lai Q; Sharma A; Xu B; Zhao Z; Feng R; Ni H; Claxton D; Guo Y; Mesa RA; Qiu Y; Yang FC; Li W; Nimer SD; Huang S; Xu M Nat Commun; 2021 Mar; 12(1):1956. PubMed ID: 33782403 [TBL] [Abstract][Full Text] [Related]
8. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia. Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876 [TBL] [Abstract][Full Text] [Related]
9. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia]. Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800 [TBL] [Abstract][Full Text] [Related]
10. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365 [TBL] [Abstract][Full Text] [Related]
11. IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia and associated with NPM1 mutations and FAB-M2 subtype. Chao HY; Jia ZX; Chen T; Lu XZ; Cen L; Xiao R; Jiang NK; Ying JH; Zhou M; Zhang R Int J Lab Hematol; 2012 Oct; 34(5):502-9. PubMed ID: 22494415 [TBL] [Abstract][Full Text] [Related]
12. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia. Nassereddine S; Lap CJ; Haroun F; Tabbara I Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344 [TBL] [Abstract][Full Text] [Related]
13. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients. Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213 [TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020 [TBL] [Abstract][Full Text] [Related]
15. [Effects of IDH2 Gene Mutation on Clinical Characteristics and Prognostic of Patients with Acute Myeloid Leukemia]. Luo LQ; Peng ZY; Liu X; Yu WZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Aug; 27(4):1077-1082. PubMed ID: 31418360 [TBL] [Abstract][Full Text] [Related]
16. Rapid detection of IDH2 (R140Q and R172K) mutations in acute myeloid leukemia. Ashraf S; Noguera NI; Di Giandomenico J; Zaza S; Hasan SK; Lo-Coco F Ann Hematol; 2013 Oct; 92(10):1319-23. PubMed ID: 23949315 [TBL] [Abstract][Full Text] [Related]
17. IDH1 and IDH2 mutations in pediatric acute leukemia. Andersson AK; Miller DW; Lynch JA; Lemoff AS; Cai Z; Pounds SB; Radtke I; Yan B; Schuetz JD; Rubnitz JE; Ribeiro RC; Raimondi SC; Zhang J; Mullighan CG; Shurtleff SA; Schulman BA; Downing JR Leukemia; 2011 Oct; 25(10):1570-7. PubMed ID: 21647154 [TBL] [Abstract][Full Text] [Related]
18. PBX3 is an important cofactor of HOXA9 in leukemogenesis. Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595 [TBL] [Abstract][Full Text] [Related]
19. The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. Lemonnier F; Cairns RA; Inoue S; Li WY; Dupuy A; Broutin S; Martin N; Fataccioli V; Pelletier R; Wakeham A; Snow BE; de Leval L; Pujals A; Haioun C; Paci A; Tobin ER; Narayanaswamy R; Yen K; Jin S; Gaulard P; Mak TW Proc Natl Acad Sci U S A; 2016 Dec; 113(52):15084-15089. PubMed ID: 27956631 [TBL] [Abstract][Full Text] [Related]
20. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Chaturvedi A; Araujo Cruz MM; Jyotsana N; Sharma A; Yun H; Görlich K; Wichmann M; Schwarzer A; Preller M; Thol F; Meyer J; Haemmerle R; Struys EA; Jansen EE; Modlich U; Li Z; Sly LM; Geffers R; Lindner R; Manstein DJ; Lehmann U; Krauter J; Ganser A; Heuser M Blood; 2013 Oct; 122(16):2877-87. PubMed ID: 23954893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]